Cutaneous toxicities induced by anti-EGFR therapy, in particular rash, are the most frequent adverse effects observed in patients with EGFR-mutant cancers, including non-small cell lung cancer, breast cancer and colorectal cancer. This evidence concerns the gene EGFR and cancer.